Copyright
©The Author(s) 2021.
World J Transplant. Jul 18, 2021; 11(7): 303-319
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Published online Jul 18, 2021. doi: 10.5500/wjt.v11.i7.303
Figure 2 Pooled risk ratio of focal segmental glomerulosclerosis recurrence between the group that received rituximab (with or without plasmapheresis) and the standard treatment group.
- Citation: Boonpheng B, Hansrivijit P, Thongprayoon C, Mao SA, Vaitla PK, Bathini T, Choudhury A, Kaewput W, Mao MA, Cheungpasitporn W. Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis. World J Transplant 2021; 11(7): 303-319
- URL: https://www.wjgnet.com/2220-3230/full/v11/i7/303.htm
- DOI: https://dx.doi.org/10.5500/wjt.v11.i7.303